Rachel Dania Melamed

Rachel Dania Melamed

Auto-generated profile, based on publicly available information

Rachel Dania Melamed

Department of Biological Sciences, University of Massachusetts, Lowell

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2011 in Science
Verified
Journal Article
Closed access
PDF file
SBSean C. Bendall
Sean C. Bendall
ESErin F. Simonds
Erin F. Simonds
PQPeng Qiu
Peng Qiu
EAEl-Ad D. Amir
El-Ad D. Amir
PKPeter O. Krutzik
Peter O. Krutzik
GNGarry P. Nolan
Garry P. Nolan
Simultaneous measurement of more than 30 properties in individual human cells is used to characterize signaling in the immune system.

1 November 2007 in Immunity
Verified
Journal Article
Closed access
JHJonathan A. Hill
Jonathan A. Hill
MFMarkus Feuerer
Markus Feuerer
KTKaley Tash
Kaley Tash
SHSokol Haxhinasto
Sokol Haxhinasto
JPJasmine Perez
Jasmine Perez
CBChristophe Benoist
Christophe Benoist

1 September 2013 in Cell
Verified
Journal Article
Closed access
DBDavid Blair
David Blair
CLChristopher S. Lyttle
Christopher S. Lyttle
JMJonathan M. Mortensen
Jonathan M. Mortensen
CBCharles F. Bearden
Charles F. Bearden
AJAnders Boeck Jensen
Anders Boeck Jensen
ARAndrey Rzhetsky
Andrey Rzhetsky

25 September 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ROReinhard Obst
Reinhard Obst
HSHisse M van Santen
Hisse M van Santen
RMRachel Melamed
Rachel Melamed
AKAlice O. Kamphorst
Alice O. Kamphorst
CBChristophe Benoist
Christophe Benoist
DMDiane Mathis
Diane Mathis
Activation of dendritic cells (DCs) enhances their ability to prime naïve T cells. How activation renders them immunogenic rather than tolerogenic is unclear. Here, we show, using temporally regulated expression of a transgene-encoded neoself antigen in DCs, that either prolonged antigen presentation or DC activation could elicit full expansion, effector cytokine production, and memory-cell differentiation. Microarray analysis of gene expression in T cells showed that all changes linked to DC activation through CD40 could be reproduced by persistent antigen delivery, suggesting that stabilization of antigen presentation is an important consequence of DC activationin vivo. In this system, DC activation by CD40 engagement indeed extended their ability to present antigen to CD4+T cellsin vivo, although different results were obtained with antigen delivered to DCs by means of endocytosis from the cell surface. These results suggest that antigen persistence may be an important discriminator of immunogenic and tolerogenic antigen exposure.

1 June 2014 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
IAIraz T. Aydin
Iraz T. Aydin
RMRachel D. Melamed
Rachel D. Melamed
SASarah J. Adams
Sarah J. Adams
MCMireia Castillo-Martin
Mireia Castillo-Martin
ADAhu Demir
Ahu Demir
JCJulide Tok Celebi
Julide Tok Celebi
Melanoma is a heterogeneous tumor with subgroups requiring distinct therapeutic strategies. Genetic dissection of melanoma subgroups and identification of therapeutic agents are of great interest in the field. These efforts will ultimately lead to treatment strategies, likely combinatorial, based on genetic information. To identify “driver” genes that can be targeted therapeutically, we screened metastatic melanomas for somatic mutations by exome sequencing followed by selecting those with available targeted therapies directed to the gene product or its functional partner. The FBXW7 gene and its substrate NOTCH1 were identified and further examined. Mutation profiling of FBXW7, biological relevance of these mutations and its inactivation, and pharmacological inhibition of NOTCH1 were examined using in vitro and in vivo assays. We found FBXW7 to be mutated in eight (8.1%) melanoma patients in our cohort (n = 103). Protein expression analysis in human tissue samples (n = 96) and melanoma cell lines (n = 20) showed FBXW7 inactivation as a common event in melanoma (40.0% of cell lines). As a result of FBXW7 loss, we observed an accumulation of its substrates, such as NOTCH1. Ectopic expression of mutant forms of FBXW7 (by 2.4-fold), as well as silencing of FBXW7 in immortalized melanocytes, accelerated tumor formation in vivo (by 3.9-fold). Its inactivation led to NOTCH1 activation, upregulation of NOTCH1 target genes (by 2.6-fold), and promotion of tumor angiogenesis and resulted in tumor shrinkage upon NOTCH1 inhibition (by fivefold). Our data provides evidence on FBXW7 as a critical tumor suppressor mutated and inactivated in melanoma that results in sustained NOTCH1 activation and renders NOTCH signaling inhibition as a promising therapeutic strategy in this setting.

1 July 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
GHGordon Hyatt
Gordon Hyatt
RMRachel Melamed
Rachel Melamed
RPRichard Park
Richard Park
RSReuben Seguritan
Reuben Seguritan
CLCatherine Laplace
Catherine Laplace
CBChristophe Benoist
Christophe Benoist